Applied Finance Capital Management LLC Sells 2,887 Shares of Johnson & Johnson $JNJ

Applied Finance Capital Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 9.6% during the 3rd quarter, Holdings Channel reports. The firm owned 27,219 shares of the company’s stock after selling 2,887 shares during the period. Applied Finance Capital Management LLC’s holdings in Johnson & Johnson were worth $5,047,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the period. Norges Bank acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $4,877,174,000. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 0.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after purchasing an additional 52,074 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on JNJ shares. Barclays upped their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. TD Cowen lifted their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Stock Down 0.6%

Shares of NYSE JNJ opened at $238.62 on Tuesday. The stock has a market capitalization of $574.90 billion, a P/E ratio of 21.59, a PEG ratio of 2.33 and a beta of 0.35. The stock’s fifty day moving average is $214.20 and its 200 day moving average is $194.70. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $240.93. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.